Janet Freeman-Daily

Writer, speaker, science geek, cancer research advocate and activist. Living with ROS1+ lung cancer since 2011. Cofounder @ros1cancer, @IASLC STARS. #LCSM

[LUNGevity Foundation @LUNGevity]

“As the Director of Translational Research at the Foundation, I get to see the everyday impact that our research and investment is making….the hope is real.”

On this #WorldCancerResearchDay, LUNGevity’s Dr. Upal Basu Roy is sharing about the Foundation’s research program, how decisions are made on what research to invest in, and its success.

Learn more about the exciting research happening at LUNGevity by visiting https://t.co/EDmdfMmIOm and support our mission of funding translational research to benefit patients by making a donation today https://t.co/8GbXXNzEP9

There has been much progress made in lung cancer research in the last 5 years but more action is needed to give every person diagnosed with lung cancer the ability to live long, fulfilling lives.

[Janet Freeman-Daily @JFreemanDaily]

#LivingWithLungCancer #WCLC2026

[Jill Feldman @jillfeldman4]

My friend @GinaHollenbeck was a fierce #lungcancer advocate—kind, smart, funny, and unafraid to challenge her own narrative.

In her powerful @IASLC #WCLC2021 talk, Gina explains why she stopped leading her story with “I didn’t smoke.” While many feel this pushes back against #stigma, she realized the binary approach of 'guilt and innocence' slows progress and perpetuates a harmful narrative that is profound and far-reaching.

Using the stigma to try to erase it only continues to label us, reduce our humanity, and our identity becomes a single story. Let's talk about RISK FACTORS. That's when people ask questions and listen!

Since Dana Reeve’s diagnosis, I’ve seen how focusing only on people who “never smoked” divides our community and completely erases the person behind the disease. The truth is simple: NO ONE earns lung cancer, and NO ONE deserves it.

Gina's message calls us back to compassion, understanding, and respect. Please listen and help change the conversation. https://t.co/GkbK6XCQ5y

#LCAM #LCSM #NoStigma @EGFRResisters @YoungLungCancer @ros1cancer @ALKPositiveinc @Exon20Group @RetRenegades @KRASKickers @NTRKers @BrafBombers @RETpositive @LUNGevity @lcrf_org @AmLungCSI @OncogeneCancer @NLCRTnews @LungCancerRx @heidi_onda @DrewMoghanaki

[Janet Freeman-Daily @JFreemanDaily]

Hm. X says my account is based in Malaysia. I was recently on a cruise from Tokyo to Bangkok with shipboard wifi provided by Starlink. I logged into X ONCE (on the South China Sea between Hong Kong and Taiwan), 100s of miles from Malaysia. Methinks the algorithm needs more work.

[Stephanie Chuang @StephChuang]

If anyone knows @DRCamidge, they know how patient-focused he's been in his 20 years of leading lung cancer research. (And funny - just ask @JFreemanDaily 😉 .)

But he hasn't been doctor only - he's been a stage 4 lung cancer patient, himself. Recently, he decided to open up about his experience after learning of his diagnosis 3 years ago.

I had the privilege of hearing more about his experience firsthand and am grateful to him for continuing to help people, in spite of his incredibly busy schedule (BTW this was the 2nd time in 1 month he gave us @Patient_Story his time. The 1st was for our partnership with @ros1cancer on an educational series).

Want inspiration on how to approach life? Take a look & listen 👇

https://t.co/WfmDnMukvR

#lungcancer #cancerawareness #stage4 #patientcare

[Janet Freeman-Daily @JFreemanDaily]

@Dr_Aggen @christine_lovly Congratulations on your new adventure!

[Janet Freeman-Daily @JFreemanDaily]

@XfinitySupport When I click on the link, my screen just goes gray--no way to send message.

[Janet Freeman-Daily @JFreemanDaily]

@ComcastCares I use @SaneBox to keep my Inbox under control but you keep blocking their access to my @comcast email account! What gives? Please stop blocking their access to my account! https://t.co/uurPc88FMq

[Janet Freeman-Daily @JFreemanDaily]

@XfinitySupport The link you shared for sending you a private message does not work.

[LUNGevity Foundation @LUNGevity]

Cancer research is not a line item. It’s a lifeline. 🔬 @ZEROcancer, @FightCRC, @LUNGevity, @PanCAN, @AACI_Cancer + @SusanGKomen join forces to urge sustained federal funding that fuels progress + saves lives. Read the special co-authored AACI Commentary https://t.co/mqSLbvvplR

[Oncology Tube @oncologytube]

📺BREAKING VIDEO Overview:
🚨FDA Approves TALETRECTINIB
🫁NSCLC ROS1+
🎉 TRUST-I Trial: 90% ORR
📊72% DOR ≥12mo naive!⏲️

📰 Article With References: https://t.co/tb2JImCV60

#CancerResearch #LungCancer #ASCO25

@imedverse
@OncoAlert
@GlopesMd
@NarjustFlorezMD
@CParkMD
@weoncologists
@CharuAggarwalMD
@AndresFCardonaZ
@DrSanjayPopat
@Larvol
@brunolarvol
@ADesaiMD
@amersameer
@DevikaDasMD
@lungoncdoc
@JFreemanDaily
@dr_yakupergun
@ONCOassist
@JulienMazieres
@RenoHemonc
@RManochakian
@IvyLorena_Md
@Fiatopichan
@MLadanyi
@LungSummit
@tnewsomdavis
@ilimlevebilimle
@medicalwatchBC
@FawziAbuRous
@myfight4cancer
@drdeniztural
@FernandoOnco
@hematologo
@gerlach_d
@DipeshUpretyMD
@TaraHerrmannPhD
@DrMirallas
@dralanreyesonco
@DMSLung
@EuniceAlejand15
@YYElamin
@Raj_Singh_MD
@Rf_Correa
@YoungLungCancer
@mtymtyyanmaz
@OncoReporte
@StephenVLiu
@Latinamd
@SuyogCancer
@ozdogan_md

[Stephen V Liu, MD @StephenVLiu]

FDA approves taletrectinib for #ROS1 NSCLC based on TRUST I and TRUST II trials showing 1L RR 85-90% with 63-72% of responses lasting ≥12 months and post TKI, RR 52-62%. Taletrectinib has selectivity over TrkB so should have less neurotoxicity.

https://t.co/kzsJQE9bAu

[Janet Freeman-Daily @JFreemanDaily]

Pleased to announce the 2024 ROS1+ Cancer Innovation Award winners! https://t.co/3DFhpakQ6i

[Matthew Herper @matthewherper]

The entire STAT staff is updating this story about layoffs at HHS. There will be a lot of info.

But the short version is this: a lot of the people who would keep drugs safe and effective, to protect patients in trials, and to fight bird flu and future pandemics are gone -- even though it seems the scientists in charge of directly reviewing new medicines are mostly protected at FDA.

Per Robert Califf: "[The FDA] as we’ve known it is finished, with most of the leaders with institutional knowledge and a deep understanding of product development and safety no longer employed.”

https://t.co/BMrVUhlqvK

[Janet Freeman-Daily @JFreemanDaily]

@matthewherper Is anyone still left at HHS research labs who can feed the research animals?

[Jill Feldman @jillfeldman4]

My approach to treatment is: I’m not looking to throw a Hail Mary touchdown — the odds aren’t in my favor. I need to keep getting first downs. First downs keep me in the game, and the longer I'm in the game, the more time research has to catch up!
22 first downs - think about all the moments and milestones this patient was able to experience with family & friends thanks to SBRT. That is HOPE!

[Janet Freeman-Daily @JFreemanDaily]

A thoughtful perspective on importance of government-supported research infrastructure. It's not perfect, and could use reform. But you can't reform something that disappeared due to lack of funding for labs, support staff, equipment and office space.

https://t.co/6lrBHSHCVc

[Janet Freeman-Daily @JFreemanDaily]

On this #WorldCancerDay, take steps to amp up your lung cancer patient advocacy! Applications are now open for the 2025 IASLC STARS PRA & Scholar Programs. STARS can help you develop and enhance research advocacy skills. https://t.co/IXZreikAa6

[Janet Freeman-Daily @JFreemanDaily]

DEI is not the same as diversity in clinical trials.

Diversity in clinical trials aims to test new drugs in a wide variety of people, because response to some medicines can vary by gender, age, ethnicity, and genetics.

https://t.co/T1gthzAmoE

[Janet Freeman-Daily @JFreemanDaily]

@OPENoncology @CrozrX @RielyMD @statnews Yes, I do. Until two days ago, the "For You" tab was a train wreck. Miraculously, after my article posted, the ads and random unwanted posts have mostly disappeared from that feed (thanks to whoever made that happen). "Following" still has tons of ads.